Clinical Trials


Combining REQORSA™ immunogene therapy with Tagrisso (osimertinib)

Preliminary analysis of the interim data from the Phase II portion of our ONC-002 trial supported our belief that REQORSA™ may provide medical benefit in several subpopulations of NSCLC patients for which there is an unmet medical need, and may provide pathways for accelerated approval by the U.S. Food and Drug Administration, or FDA. Data from our clinical trials, along with our preclinical data, provided the basis for our application for a Fast Track Designation, which was granted by FDA on January 14, 2020. 

In granting our Fast Track Designation, the FDA found that REQORSA may provide a benefit over existing therapies for patients whose tumors progress on AstraZeneca’s Tagrisso. The FDA Fast Track Designation is for use of the combination of REQORSA with Tagrisso in patients whose tumors progressed on Tagrisso. We believe that the Fast Track Designation provides a clearly defined pathway toward FDA approval of the combination of REQORSA with Tagrisso, and we plan to initiate a Phase 1/2 clinical trial of REQORSA combined with Tagrisso in 2021. Based on the receipt of the Fast Track Designation of REQORSA with Tagrisso and the fact that Tagrisso is now the standard of care for this patient population, we will no longer enroll patients in our ONC-002 trial in which we combined REQORSA with Tarceva.

To learn more about scientific evidence and studies supporting REQORSA and the TUSC2 gene, please refer to our TUSC2 Bibliography page.

Tagrisso® is a registered trademark of AstraZeneca.

Tarceva® is a registered trademark of Astellas and the Roche Group of companies.